American Association for Cancer Research
00085472can170740-sup-179151_2_supp_4281743_fwkszk.doc (776.5 kB)

Supplemental Figure 1 from IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer

Download (776.5 kB)
journal contribution
posted on 2023-03-31, 01:06 authored by Purushottam Lamichhane, Lavakumar Karyampudi, Barath Shreeder, James Krempski, Deborah Bahr, Joshua Daum, Kimberly R. Kalli, Ellen L. Goode, Matthew S. Block, Martin J. Cannon, Keith L. Knutson

Expression of PD-1 on BMDCs and T cells after exposure to IL-6 and IL-10


Minnesota Ovarian Cancer Alliance

the Fred C. and Katherine B. Andersen Foundation

Marsha Rivkin Center For Ovarian

Mayo Clinic



Ligation of programmed cell death-1 (PD-1) in the tumor microenvironment is known to inhibit effective adaptive antitumor immunity. Blockade of PD-1 in humans has resulted in impressive, durable regression responses in select tumor types. However, durable responses have been elusive in ovarian cancer patients. PD-1 was recently shown to be expressed on and thereby impair the functions of tumor-infiltrating murine and human myeloid dendritic cells (TIDC) in ovarian cancer. In the present work, we characterize the regulation of PD-1 expression and the effects of PD-1 blockade on TIDC. Treatment of TIDC and bone marrow–derived dendritic cells (DC) with IL10 led to increased PD-1 expression. Both groups of DCs also responded to PD-1 blockade by increasing production of IL10. Similarly, treatment of ovarian tumor–bearing mice with PD-1 blocking antibody resulted in an increase in IL10 levels in both serum and ascites. While PD-1 blockade or IL10 neutralization as monotherapies were inefficient, combination of these two led to improved survival and delayed tumor growth; this was accompanied by augmented antitumor T- and B-cell responses and decreased infiltration of immunosuppressive MDSC. Taken together, our findings implicate compensatory release of IL10 as one of the adaptive resistance mechanisms that undermine the efficacy of anti–PD-1 (or anti–PD-L1) monotherapies and prompt further studies aimed at identifying such resistance mechanisms. Cancer Res; 77(23); 6667–78. ©2017 AACR.

Usage metrics

    Cancer Research



    Ref. manager